RemeGen Co Ltd Class H REGMF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.01
- Day Range
- $2.09–2.09
- 52-Week Range
- $2.01–7.15
- Bid/Ask
- $3.25 / $5.50
- Market Cap
- $1.14 Bil
- Volume/Avg
- 200 / 1,924
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.42
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 3,615
- Website
- https://www.remegen.com
Comparables
Valuation
|
Metric
|
REGMF
|
KNSA
|
02315
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 181.64 | — |
Price/Book Value | 2.35 | 3.28 | 4.47 |
Price/Sales | 7.42 | 4.78 | 4.88 |
Price/Cash Flow | — | 121.32 | — |
Price/Earnings
REGMF
KNSA
02315
Financial Strength
|
Metric
|
REGMF
|
KNSA
|
02315
|
|---|---|---|---|
Quick Ratio | 1.04 | 3.57 | 1.02 |
Current Ratio | 1.96 | 4.21 | 1.30 |
Interest Coverage | −65.67 | — | −5.27 |
Quick Ratio
REGMF
KNSA
02315
Profitability
|
Metric
|
REGMF
|
KNSA
|
02315
|
|---|---|---|---|
Return on Assets (Normalized) | −24.32% | 8.64% | −13.53% |
Return on Equity (Normalized) | −33.25% | 10.14% | −37.28% |
Return on Invested Capital (Normalized) | −28.59% | 9.90% | −20.22% |
Return on Assets
REGMF
KNSA
02315
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fbmzsgbbc | Mtyv | $567.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qnyjxqs | Jshznw | $106.9 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tsnrtdbyw | Znyhpd | $104.0 Bil | |
MRNA
| Moderna Inc | Khqjztcd | Tczb | $46.4 Bil | |
ARGX
| argenx SE ADR | Spfbbxjz | Jmtwt | $23.2 Bil | |
BNTX
| BioNTech SE ADR | Cxhnjykb | Ccsx | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Czqpsnc | Xqklyn | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Czksyglzx | Zdtntdt | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pcvzffbwb | Kjjvmy | $12.7 Bil | |
INCY
| Incyte Corp | Zypztrdj | Cckgnl | $12.2 Bil |